Figure 2 (IMAGE)
Caption
Whole-genome sequence determinations of HCT-116 (colon cancer cells) and U2OS (osteosarcoma cells) revealed that there are many InDel mutations specific for HCT-116 and U2OS. When researchers delivered HCT-116 or U2OS InDel targeting CRISPR-Cas9s to U2OS cells, only U2OS InDel targeting CRISPR-Cas9 caused U2OS cancer cell death, which confirms the high specificity of CINDELA technology.
Credit
Institute for Basic Science
Usage Restrictions
Attribution Required
License
Original content